Results 111 to 120 of about 24,049 (149)
Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. [PDF]
OncologistAntonuzzo L, Takahashi H, Park JO, Sookprasert A, Gillmore R, Yang SS, Cundom J, Petrova M, Vaccaro G, Holmblad M, Żotkiewicz M, Wang J, Rokutanda N, Oh DY. +13 moreeuropepmc +1 more sourceSupplementary Figure S4 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
Xavier García del Muro, Begoña P. Valderrama, Ana Medina, Olatz Etxániz, Regina Gironés Sarrió, María José Juan-Fita, Marcel Costa-García, Rafael Moreno, Isabel Miras Rodríguez, Irene Ortiz, Andrés Cuellar, Ferrán Ferrer, Francesc Vigués, Roberto de Haro Piedra, Arturo Candal Gómez, S. Villà, José Luís Pontones, Yasmina Murria, Guillermo Lendínez‐Cano, Ramón Alemany +19 moreopenalex +1 more sourceEfficacy of Immune Checkpoint Inhibitors in Combination With Platinum-Based Doublet Chemotherapy for Extensive-Stage Small-Cell Lung Cancer Patients With Eastern Cooperative Oncology Group-Performance Status 2-3: A Single-Institution Retrospective Study. [PDF]
Cancer MedSakai K, Ishii S, Yokosuka S, Takahashi T, Kawano Y, Nishimura H, Kuwabara Y, Sasaki-Toda M, Ogawa-Kobayashi Y, Kikuchi S, Hirata Y, Kyoyama H, Moriyama G, Koyama N, Uematsu K. +14 moreeuropepmc +1 more sourceFigure 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
John D. Powderly, Martina Imbimbo, Antoîne Italiano, Patricia Martín-Romano, Meredith McKean, Teresa Macarulla, Eduardo Castañón Álvarez, Benedito A. Carneiro, Raymond Mager, Vicky Barnhart, Steven Eck, Elina Murtomaki, Arsène‐Bienvenu Loembé, Yun He, Zachary A. Cooper, Eric Tu, Chunling Fan, Agnes Boyer Chamard, Carine Paturel, Paula G. Fraenkel, Antoine Hollebecque +20 moreopenalex +1 more sourceThe effect of durvalumab consolidation after definitive radiochemotherapy for non-operable stage III non-small cell lung cancer on the dose effect relation for therapy related pulmonary infiltrates as a risk factor for pneumonitis. [PDF]
Transl Lung Cancer ResHerz A, Guberina M, Pöttgen C, Gauler T, Ton TTM, Fischedick G, Kiwitt LO, Lübcke W, Hoffmann C, Schuler M, Metzenmacher M, Schaarschmidt BM, Bos D, Opitz M, Hautzel H, Darwiche K, Bölükbas S, Grapatsas K, Jendrossek V, Gockeln L, Wirsdörfer F, Hetzel M, Mladenov E, Stuschke M, Guberina N. +24 moreeuropepmc +1 more source
